tbuckley/cabot-search huggingface dataset:
Statins and survival in a cohort of veterans with chronic lymphocytic leukemia (CLL).
Authors: Abdullah Mohammad Khan, Vinnidhy Dave, Shanti Srinivas, Victor Tsu-Shih Chang, Monica McPherson, Basil Kasimis
Journal: Journal of Clinical Oncology (2014)

1610 Background: CLL is the most prevalent leukemia in the Veteran (V) population but there is limited information on the clinical characteristics and risk factors in this population. We hypothesized that statins might have a protective effect based on earlier work (ASCO 2013). Methods: In an IRB approved protocol, a retrospective cohort of 130 V diagnosed with CLL from 2001 to 2013 were reviewed for demographic, clinical, and laboratory data. Comorbidity was assessed using Charlson Comorbidity Index (CCI), The Kaplan-Feinstein Index (KFI), and the Cumulative Illness Rating Scale (CIRS). Cox regression analysis was performed using STATA 13. Results: The median (M) age was 72 years (34-94), height 69.5 inches (60-99), weight 190 pounds (99-287.5), and BMI 27.4 kg/m2 (15.54-42). 42 (32.3 %) served in the Vietnam War and 88 (67.7%) served during World War II and the Korean conflict. At diagnosis, 129 (99%) V had an ECOG Performance Status (PS) of 0-2, 111 (85%) had Rai stage 0-2 disease, and 81 (62%) were on statins. M hemoglobin was 13.6 g/dl (7.3-17.2), white blood cell count 15.8 K/cmm (3.6-282), absolute lymphocyte count 9.35 K/cmm (1.6-161.1), blood urea nitrogen (BUN) 19 mg/dL (4-88), creatinine 1.1 mg/dl (0.4-3.6), albumin 4.2 (2-4.8), lactate dehydrogenase 182 IU/L (101-1635), and beta 2-microglobulin 2.3 mg/dl (0.9-10.9). By immunophenotyping 35 (26.9%) were CD38/ ZAP-70 positive. The CCI was 4.1 (0-9.0), KFI 1 (0-3), CIRS 15 3 (1-6), CIRS 16 6 (1-14), CIRS 17 2 (0-4.5), CIRS 18 0 (0-1), CIRS 19 0 (0-1). The M survival was 1625 days (4-7502). In univariate analysis, age (p<0.04), height (p <0.05), BUN (P<0.02), and albumin (P<0.01) predicted survival. In multivariate analysis, statin use (p< 0.017), CD38/ZAP 70 (p <0.013) and CIRS 17 (p <0.022) were able to predict survival. Conclusions: In our study, patients with older age, good PS, and early CLL, statin use was a significant predictor of survival. These findings need to be evaluated in a larger cohort. Statin use may be an important stratification criteria for future trials.
Abstract 18557: Cardiovascular Risk Factor Trajectories From Childhood to Adulthood and Depression in Middle Age: The Bogalusa Heart Study
Authors: Patrick Stuchlik, Norrina Allen, Emily Harville, Wei Chen, Lydia Bazzano
Journal: Circulation (2015)

Introduction: It is well known that depression and heart disease are closely linked. However, it remains unclear whether changes in cardiovascular (CV) risk factors over time may be related to depression. Few studies have examined the long term patterns of CV risk factors in relation to depression in middle age. Hypothesis: The trajectories of cardiovascular risk factors are associated with depression and depressive symptoms. Methods: We examined data from the Bogalusa Heart Study, a long-term community-based observational study of a biracial cohort, with first measurements in childhood in 1976. Men and women who completed the CES-D in 2010 with at least two childhood and two adult CV measurements (n=913) were included. Age, systolic blood pressure, antihypertensive treatment status, smoking status, total and HDL cholesterol, were used to calculate standardized 10-year Framingham CV risk scores at each follow-up. CES-D scores were categorized using established cut points (&lt;8, 8-15, &gt;15). Discrete mixture modeling was employed to identify trajectory groupings of CV risk. The association between CV risk score trajectory and CES-D were determined using multivariable logistic regression adjusted for smoking, education, physical activity, and BMI in 2010. Results: Mean (±SD) age was 43.06±4.48 years, 57.9% were female, and 31.7% were black race. 27.7% of participants were current smokers in 2010. Mean (±SD) BMI was 30.97±7.73. We identified three CV risk patterns: stable (63.8%), slightly elevated (28.8%), and increasingly elevated (7.5%). Relative to stable CV risk, the multivariable adjusted odds ratio of higher CES-D categorization, i.e. more depressed, for slightly elevated was 1.49 (95% CI, 1.08-2.06), and for increasingly elevated, 1.53 (95% CI, 0.90-2.59). Smokers had increased odds of higher CES-D categorization over nonsmokers (OR=2.16, 95% CI 1.58-2.95). One-unit increases of BMI were associated with 1.02 times greater odds of higher CES-D categorization (95% CI, 1.01-1.04). Conclusions: Trajectories of cardiovascular risk from childhood through adulthood are associated with depression in middle age. Individuals with elevated or increasing cardiovascular risk profiles may benefit from depression screening in early middle age.
Perspectivas de um futuro brilhante para a formação em epidemiologia de campo na Europa
Authors: Arthur L. Reingold
Journal: Eurosurveillance (2001)

A publicacao de uma serie de artigos sobre os varios programas de formacao em epidemiologia em 2001 coincide com o 50o aniversario do Epidemic Intelligence Service (EIS) dos Centers for Disease Control and Prevention (CDC). Se ainda fosse vivo, Alex Langmuir (fundador do EIS) ficaria bastante satisfeito ao constatar a multiplicacao e sucesso que os programas de formacao obtiveram na Europa. Tambem na America Latina, Asia e Africa estao a surgir programas de formacao praticos identicos, destinados a fornecer aos profissionais de saude as capacidades praticas necessarias a execucao de investigacoes epidemiologicas relevantes e oportunas no mundo real da saude publica. Alguns destes programas de formacao estao a ser desenvolvidos e sao propostos por varias instituicoes academicas locais, outros envolvem parcerias formais com os CDC e outros resultam dos esforcos isolados das agencias locais de saude publica.
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function
Authors: Federico Gulluni, Miriam Martini, Maria Chiara De Santis, Carlo Cosimo Campa, Alessandra Ghigo, Jean Piero Margaria, Elisa Ciraolo, Irene Franco, Ugo Ala, Laura Annaratone, Davide Disalvatore, Giovanni Bertalot, Giuseppe Viale, Anna Noatynska, Mara Compagno, Sara Sigismund, Filippo Montemurro, Marcus Thelen, Fan Fan, Patrick Meraldi, Caterina Marchiò, Salvatore Pece, Anna Sapino, Roberto Chiarle, Pier Paolo Di Fiore, Emilio Hirsch
Journal: Cancer Cell (2017)
Efficacité du vaccin anti-grippal lors d'une épidémie de grippe A dans une maison de retraite des Pyrénées Atlantiques, France, novembre - décembre 1995
Authors: A Infuso, S Baron, H Fauveau, M Melon, H Fleury, J C Desenclos
Journal: Eurosurveillance (1996)

Dans la region des Pouilles situee dans le sud-est de l'Italie (population : 4 millions), le nombre de declarations d'infection par le virus de l'hepatite A (VHA) augmente tous les deux ans. En 1992, une epidemie tres importante a ete observee mais aucune investigation epidemiologique n'avait ete realisee. La plupart des cas sont declares en debut d'annee (figure 1). Fin 1995, la region des Pouilles a integre le projet national d'informatisation du systeme de surveillance des maladies infectieuses (Sistema Informatizzato sulle Malattie Infettive, SIMI).
Patterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study
Authors: R. Marconcini, E. Marra, F. De Rosa, L.S. Stucci, L. Orgiano, S. Ribero, F. Bloise, A. Antonuzzo, A. Falcone
Journal: Annals of Oncology (2017)
Endoscopic mucosa–submucosal clip closure method
Authors: Shigeo Banno, Toshihiro Nishizawa, Satoshi Kinoshita, Hideki Mori, Toshio Uraoka
Journal: Endoscopy (2017)

It is desirable to perform a prophylactic closure using endoclips in patients who are at high risk of delayed bleeding or perforation after endoscopic resection [1]. A mucosal defect after endoscopic mucosal resection can be closed with sequential endoclips as if zipping up the mucosal edges. However, it is difficult to close a large mucosal defect after endoscopic submucosal dissection (ESD) using only conventional endoclips. Several methods have been reported, such as the "slip knot clip suturing method" [2] and the "endoscopic hand-suturing" technique [3]. However, these endoscopic closure methods can be difficult, and require a string or special device, which is not always available and takes time to apply. This report describes a simpler closure method using conventional endoclips.
Mood Instability and Reward Dysregulation—A Neurocomputational Model of Bipolar Disorder
Authors: Liam Mason, Eran Eldar, Robb B. Rutledge
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
A Call for Open Access and Empathy Is Not Enough: Hands on Are Needed!
Authors: Ingrid Miljeteig, Frehiwot Berhane, Dawit Desalegn
Journal: The American Journal of Bioethics (2017)

This article refers to:A Question of Social Justice: How Policies of Profit Negate Engagement of Developing World Bioethicists and Undermine Global Bioethics
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
Authors: Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel
Journal: Thorax (2017)

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.
Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding
Authors: Deguan Lv, Feng Jia, Yanli Hou, Youzhou Sang, Angel A. Alvarez, Weiwei Zhang, Wei-Qiang Gao, Bo Hu, Shi-Yuan Cheng, Jianwei Ge, Yanxin Li, Haizhong Feng
Journal: Cancer Research (2017)

Abstract Lysine acetyltransferase KAT6A is a chromatin regulator that contributes to histone modification and cancer, but the basis of its actions are not well understood. Here, we identify a KAT6A signaling pathway that facilitates glioblastoma (GBM), where it is upregulated. KAT6A expression was associated with GBM patient survival. KAT6A silencing suppressed cell proliferation, cell migration, colony formation, and tumor development in an orthotopic mouse xenograft model system. Mechanistic investigations demonstrated that KAT6A acetylates lysine 23 of histone H3 (H3K23), which recruits the nuclear receptor binding protein TRIM24 to activate PIK3CA transcription, thereby enhancing PI3K/AKT signaling and tumorigenesis. Overexpressing activated AKT or PIK3CA rescued the growth inhibition due to KAT6A silencing. Conversely, the pan-PI3K inhibitor LY294002 abrogated the growth-promoting effect of KAT6A. Overexpression of KAT6A or TRIM24, but not KAT6A acetyltransferase activity–deficient mutants or TRIM24 mutants lacking H3K23ac-binding sites, promoted PIK3CA expression, AKT phosphorylation, and cell proliferation. Taken together, our results define an essential role of KAT6A in glioma formation, rationalizing its candidacy as a therapeutic target for GBM treatment. Cancer Res; 77(22); 6190–201. ©2017 AACR.
GW28-e0776 Three Year Follow-Up of Patients with Left Ventricular Dysfunction Causing Ischemia and Patent Coronary Arteries
Authors: Thach Nguyen, Tran Ngoc Minh Chau, Hanh Nguyen Hieu Le, Nguyen Minh Tri Nhan, Khanh Duong, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2017)
Surveillance de la sensibilité aux antibiotiques des Salmonella
Authors: A Brisabois, I Cazin, J Breuil, E Collatz
Journal: Eurosurveillance (1997)

L'Organisation Mondiale de la Sante a dernierement signale l'augmentation alarmante de l'incidence de souches de Salmonella resistantes aux antibiotiques qui serait due a l'utilisation des antibiotiques dans les elevages intensifs. En France jusqu'a ces dernieres annees, les salmonelles isolees en clinique humaine ne presentaient en general pas ou peu de resistance aux antibiotiques et le traitement antibiotique (non systematique) d'une salmonellose ne posait pas ou peu de problemes therapeutiques. Cependant depuis une vingtaine d'annee, le Centre de serotypage du CNEVA-Paris effectue une surveillance de la resistance aux antibiotiques des souches qu'il recoit ; parallelement le CNEVA-Lyon a constitue un reseau de surveillance de la resistance aux antibiotiques des principales bacteries pathogenes chez les bovins et, en particulier, des salmonelles.
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Authors: Bijal D. Shah, William G. Wierda, Gary J. Schiller, Michael Russell Bishop, Januario E. Castro, Marianna Sabatino, Adrian Bot, Armen Mardiros, John Rossi, Yizhou Jiang, Lynn Navale, Shanna Stout, Jeff Aycock, Jeffrey S. Wiezorek, Rajul K. Jain
Journal: Journal of Clinical Oncology (2017)

3024 Background: Promising results have been observed with KTE-C19, an anti-CD19 CAR T cell therapy, in refractory aggressive NHL in the ZUMA-1 trial (Blood 2016;128:LBA-6). We present here updated results from the ZUMA-3 phase 1 trial of KTE-C19 in adult patients (pts) with R/R ALL. Methods: Adult (≥18 y) pts with R/R ALL (Ph+ eligible), ≥25% bone marrow (BM) blasts, adequate organ function and ECOG status 0-1 received 1 or 2×10 6 CAR T cells/kg after conditioning with cyclophosphamide + fludarabine. Phase 1 primary endpoint is incidence of dose-limiting toxicity (DLT). Secondary endpoints include efficacy outcomes and biomarker associations. Results: As of Nov 1, 2016, 11 pts were enrolled; 10 received KTE-C19. One pt had a serious adverse event (SAE) prior to dosing and was not treated. KTE-C19 was successfully manufactured in all pts across a broad range of baseline absolute lymphocyte counts in 6 days in a centralized facility, with an approximate 2-week turnaround time. Pts were 60% men with 1-4 prior lines of therapy and high disease burden (median, 70% BM blasts). No pt (0/3) experienced a DLT at the 2×10 6 dose. Phase 1 was expanded to 6 pts at the same dose; 1 grade (Gr) 5 AE (multiorgan failure due to cytokine release syndrome [CRS]) was observed. Subsequent pts (4) received 1×10 6 CAR T cells/kg. Overall, the most common Gr≥3 AEs were cytopenias (80%), febrile neutropenia (50%), pyrexia (40%), and transaminitis (40%). Gr≥3 CRS and neurologic events (NEs) were reported in 20% and 40% of pts, respectively. Cerebral edema was not observed. All CRS (except Gr5) and 5 of 6 NEs (1 Gr3 ongoing at cut-off) resolved. Of the 8 efficacy evaluable pts, 6 achieved an MRD-negative (MRD – ) complete response (CR, or CR + partial or incomplete hematopoietic recovery). Updated results will include additional pt follow-up and biomarker data. Conclusions: No DLTs were observed with KTE-C19 in adult pts with high BM disease burden; one pt had G5 CRS after the DLT cohort. Manufacturing was successful in all pts; most pts achieved an MRD – CR. Based on these results, ZUMA-3 continues to enroll pts with additional measures implemented to further enhance safety. Clinical trial information: NCT02614066.
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
Authors: Sheng Chih Jin, Jason Homsy, Samir Zaidi, Qiongshi Lu, Sarah Morton, Steven R DePalma, Xue Zeng, Hongjian Qi, Weni Chang, Michael C Sierant, Wei-Chien Hung, Shozeb Haider, Junhui Zhang, James Knight, Robert D Bjornson, Christopher Castaldi, Irina R Tikhonoa, Kaya Bilguvar, Shrikant M Mane, Stephan J Sanders, Seema Mital, Mark W Russell, J William Gaynor, John Deanfield, Alessandro Giardini, George A Porter, Deepak Srivastava, Cecelia W Lo, Yufeng Shen, W Scott Watkins, Mark Yandell, H Joseph Yost, Martin Tristani-Firouzi, Jane W Newburger, Amy E Roberts, Richard Kim, Hongyu Zhao, Jonathan R Kaltman, Elizabeth Goldmuntz, Wendy K Chung, Jonathan G Seidman, Bruce D Gelb, Christine E Seidman, Richard P Lifton, Martina Brueckner
Journal: Nature Genetics (2017)
Orthotopic versus subcutaneous NET: tumor tissue characteristics result in different answers when ADC is used to validate early therapy response following Peptide Receptor Radionuclide Therapy (PRRT)
Authors: E.J. Koziolek, J. Albrecht, S. Exner, V. Prasad, C. Grötzinger, W. Brenner
Journal: Annals of Oncology (2017)
Indications for anticoagulant and antiplatelet combined therapy
Authors: Christopher N Floyd, Albert Ferro
Journal: BMJ (2017)

#### What you need to know

Antithrombotic medications reduce thromboembolic events by inhibiting platelet aggregation and coagulation. Antiplatelet drugs and oral anticoagulants are examples of antithrombotic medications and are among the most commonly prescribed drugs in both primary and secondary care.1 Clinicians are familiar with their use, however antiplatelets and oral anticoagulants are the drug classes most commonly implicated in adverse drug reactions occurring both in the community and in hospital.23 Increasing numbers of patients have an indication for combination antiplatelet and oral anticoagulant therapy. For example, more than one million people in the UK have atrial fibrillation, of whom approximately one third also have an indication for antiplatelet therapy as secondary prevention.4 Despite the need to understand the balance between benefit and risk, there are limited randomised data investigating antithrombotic co-prescription. Current guidelines are therefore based on expert opinion and the extrapolation of non-randomised data.

Patients can develop independent indications for antiplatelet and oral anticoagulant therapy, but in most cases the pathophysiology will intersect. The relationship between cardiovascular disease and atrial fibrillation is the typical example, where one fifth of patients presenting with atrial fibrillation will subsequently require coronary intervention, and up to one fifth of acute coronary syndrome (including ST elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina) presentations develop atrial …
Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer
Authors: J. Bosch-Barrera, E. Sais, A. Izquierdo, A. Hernández, D. Roa, E. Cuyas, S. Pedraza, N. Priego, P. Ortuño, G. Sánchez, N. Cañete, A. Roselló, R. Soffietti, J. Brunet, M. Valiente, J.A. Menendez
Journal: Annals of Oncology (2017)
La coqueluche dans les hôpitaux en France: les résultats de 10 ans de surveillance
Authors: I Bonmarin, D Lévy-Bruhl, S Baron, N Guiso, E Njamkepo, V Caro
Journal: Eurosurveillance (2007)

Cet article presente 10 annees de donnees de surveillance du reseau Renacoq. Ce reseau hospitalier pediatrique a ete mis en place en 1996 en France metropolitaine pour suivre l’evolution de la coqueluche chez les enfants et mesurer l’impact des strategies vaccinales. Les microbiologistes des 43 hopitaux participant a ce reseau sur la base du volontariat declarent les cas de coqueluche, et les pediatres remplissent un questionnaire pour chaque enfant de moins de 6 mois repondant a la definition d’un cas microbiologie, clinique ou epidemiologique. Le reseau couvre environ 30% des cas de coqueluche observes dans les hopitaux francais.
La borreliosis de Lyme crónica y diseminada en Noruega, 1995-2004
Authors: K Nygård, A B Brantsaeter, R Mehl
Journal: Eurosurveillance (2005)

La borreliosis de Lyme es la mas comun de las infecciones transmitidas por garrapatas en Noruega. Todas las manifestaciones clinicas de esta enfermedad, excepto el eritema migratorio, son de declaracion obligatoria al Instituto noruego de salud publica (Folkehelseinstituttet). Entre 1995 y 2004, se declararon un total de 1.506 casos de borreliosis de Lyme cronica y diseminada. El diagnostico de laboratorio se basaba en los tests serologicos en casi todos los casos. El numero anual de casos no indica ninguna tendencia clara para el periodo, pero oscilo entre 120 y 253 casos, con una incidencia mayor en 2004. En el 75% de los casos de los que se disponia de informacion, los pacientes mostraron los primeros sintomas entre junio y octubre. Las tasas de incidencia muestran una variacion geografica importante, situandose las mas altas en las zonas costeras del sur y del centro de Noruega. El 56% de los casos eran varones y el 44% mujeres. Los ninos entre cinco y nueve anos eran los que presentaban mayores tasas. La manifestacion clinica mas frecuente (71%) era la neuroborreliosis, seguida por artritis/artralgia (22%) y acrodermatitis cronica atrofiante (5%). Fueron hospitalizados el 46% de los pacientes. Las medidas preventivas contra la borreliosis en Noruega consisten en evitar las picaduras de garrapatas protegiendose con la ropa y usando repelentes de insectos, y en su deteccion precoz y eliminacion. En Noruega, generalmente no se recomienda el uso de antibioticos como medida profilactica tras una picadura de garrapatas.